OpenWay recognized as Best-in-Class in Datos Insights' 2025 Matrix for Merchant Acquiring Platforms
In this year's evaluation, Way4 received the highest score on the Strength/Capability axis, confirming that the platform sets the standard in product depth, multifunctionality, and flexibility.
Way4 Merchant Acquiring empowers top-tier acquiring banks, processors, and ambitious fintechs in the Americas, Europe, MENA, and APAC to launch, scale, and tailor their merchant services — with fast time to market, real-time operations, high-volume performance, and the flexibility and speed of innovation. Built for global growth and local success, the platform supports a "glocal" service model that combines international best practices with local cultural and regulatory expertise in the time zone of the client.
The platform enables a complete merchant lifecycle: from digital onboarding to dynamic and risk-based pricing, omnichannel and multi-asset acceptance (POS, e-commerce, softPOS, cards, wallets, crypto, CBDCs, A2A), real-time clearing, and reporting. Way4 also offers rich APIs, tokenization, FX tools, DCC, MCP, streaming analytics, and data-driven loyalty — as well as composable architecture that allows institutions to configure ~95% of product logic via parameters, without coding.
"We are honored by this recognition from Datos Insights. It reaffirms our strategic focus and our commitment to helping clients grow and differentiate their acquiring business," says Paul Gubin, CEO of OpenWay. "We thank our clients for their partnership and trust, and our global team for consistently delivering at the highest level."
This recognition continues OpenWay's history of industry leadership. Over the past decade, Way4 has been ranked Best-in-Class by Aite (now Datos Insights), Gartner, PayTech, Juniper Research, and Ovum for enabling first-to-market innovations in digital wallets, card management, CaaS, and cloud payment processing.
Ron van Wezel, Strategic Advisor at Datos Insights, commented:
"The Datos Matrix helps acquirers identify the vendors best positioned to support their growth and innovation. OpenWay's strong position in the 2025 Matrix reflects its clear product strategy, robust platform capabilities, and alignment with the needs of modern acquirers. Way4 stands out for its flexibility, breadth, and innovation — all critical for supporting the future of merchant services."
Thad Peterson, Strategic Advisor at Datos Insights, added:
"The merchant acquiring market is undergoing a rapid transformation. New payment methods, embedded finance, and demand for real-time services are reshaping what acquirers need from their platforms. Solutions like Way4 that combine flexibility, scalability, and global-local adaptability are exactly what leading institutions are looking for today."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
2 hours ago
- Korea Herald
Seegene Unveils CURECA™ and STAgora™ at ADLM 2025, Advancing the Next Stage of Diagnostics
SEOUL, South Korea, Aug. 5, 2025 /PRNewswire/ -- Seegene Inc., a global leader in molecular diagnostics, unveiled two new technologies at ADLM 2025 in Chicago (July 29–31) designed to advance laboratory automation and data-driven infectious disease monitoring. The company introduced CURECA™, world's first fully unattended PCR automation system, and STAgora™, a real-time data analytics platform intended to support earlier detection and precision care. Chairman Highlights Next Step in Molecular Diagnostics "With CURECA™ and STAgora™, we are taking an important step toward the future of diagnostics," said Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, during a press conference with U.S. and global media on July 30. "Our goal is to enable laboratories worldwide to automate complex testing workflows and use diagnostic data more effectively, ultimately helping advance global efforts toward a world free from diseases." Today, most molecular testing systems remain only partially automated, dependent on skilled personnel for repetitive manual steps and fixed workflows that limit efficiency and scalability. CURECA™ Breaks the Limits of Automation to Reshape Global Diagnostics CURECA™ is the first system in the diagnostics industry designed to fully automate every step of PCR testing, including the traditionally manual pre-treatment stage. Seegene notes that achieving true full automation in diagnostics requires three key conditions: operation without highly trained professionals, continuous 24-hour processing, and uninterrupted specimen input. CURECA™ is designed to meet all three. Its dedicated module, CURECA™ Prep, processes a wide range of specimen types such as urine, blood, sputum, and stool, addressing one of the most persistent barriers to automation. With the module handling diverse specimen pre-treatment, the full CURECA™ system completes the entire PCR workflow from sample loading through nucleic acid extraction, amplification, and result analysis without manual intervention. The system is engineered for continuous 24-hour operation, aiming to minimize human error, improve workflow efficiency, and allow laboratories to allocate skilled staff to higher-value activities. Full automation has long been a challenge in diagnostics due to specimen variability and the reliance on trained personnel for repetitive pre-processing tasks. CURECA™ is intended to help laboratories overcome these constraints by providing a scalable and adaptable system that can be configured to fit different lab sizes and workflows. CURECA™ Prep could also potentially extend to other testing fields, such as clinical chemistry and immunodiagnostics, as Seegene continues to explore broader automation solutions. STAgora™ Transforms Diagnostic Data into Real-Time Clinical Intelligence STAgora™ is Seegene's latest platform, designed to collect and analyze PCR testing data in real time, providing laboratories with broader context to inform diagnostic workflows. The platform includes more than 40 analytical tools, offering functions such as infection trend tracking, hospital-level positivity monitoring, and multi-pathogen co-infection pattern analysis. Rather than serving as a simple data repository, STAgora™ is built as an integrated platform intended to help laboratories derive meaningful, aggregated insights from testing data. Today, individual test results often provide limited information without broader reference points. STAgora™ is designed to address this by enabling hospitals to build their own statistical datasets and compare aggregated data across institutions, helping them detect infection patterns faster and support more informed decision-making. The data shared through the platform is de-identified and formatted according to each institution's requirements, supporting secure, real-time exchange at local, national, or global levels. Advancing Toward a World Free from All Diseases Dr. Chun reiterated Seegene's long-term vision of building "a world free from diseases" noting that the introduction of CURECA™ and STAgora™ completes the company's five core technology pillars. These include Seegene's proprietary PCR technology, the SGDDS (Seegene Digitalized Development System) for automated assay development, its global Technology-Sharing Initiative, and now the addition of fully automated PCR testing and real-time data analytics capabilities. Industry experts at ADLM 2025 expressed strong interest in Seegene's new technologies. Jamel Giuma, President and CEO of Miami based laboratory IT consulting firm JTG Consulting Group, said, "I've attended many ADLM conferences over the years, and CURECA™ is one of the most innovative solutions I have seen so far. I believe it has the potential to simplify laboratory workflows, reduce the burden on lab personnel, and greatly enhance overall operational efficiency." "With CURECA™ and STAgora™, we're addressing long-standing barriers in molecular diagnostics," Dr. Chun added. "Just as smartphones and electric vehicles transformed their industries, we believe these technologies will redefine what is possible in diagnostic testing, helping laboratories worldwide achieve true automation, unlock the value of diagnostic data, and ultimately contribute to building a world free from diseases." Disclaimer CURECA™ and STAgora™ demonstrated at ADLM 2025 are pre-commercial technologies under development, not commercially available, and are not currently cleared for clinical diagnostic use in any jurisdiction.
Korea Herald
5 hours ago
- Korea Herald
iNtRON Bio, Demonstrated Toxin-Neutralizing Effect of IMPA™ Phage Engineering Technology in Colorectal Cancer Model and Completed the US Patent Application
• Successful validation of payloaded anti-colibactin toxin phage using IMPA ™ technology • Demonstrated ' Dual-target Therapeutic Strategy ' by bacterial eradication and toxin neutralization • Filed the US patent application for the candidate substance and preclinical studies including PoC underway BOSTON and SEOUL, South Korea, Aug. 5, 2025 /PRNewswire/ -- Recently, a specific genotype of E. coli that may cause colorectal cancer has been detected in commonly eaten leafy vegetables such as lettuce, raising consumer concerns. Among these strains, pks+ E. coli is of particular concern. This bacterium produces a toxic substance in the intestine that causes DNA damage (ICLs, Interstrand Cross-Links), which leads to DSBs (Double Strand Breaks), and has been shown in numerous studies, including Nature (2023), to increase the risk of colorectal cancer over time. Amid this situation, as an innovative bacteriophage technology development company, iNtRON Bio proposes a new possibility for microbiome-based anticancer drugs in treating colorectal cancer—considered a hard-to-treat disease—by applying our phage engineering technology called IMPA™. iNtRON Bio has been developing PHAGERIA Ⓡ, an immunotherapeutic targeting gut bacteria, and through the IMPA™ phage engineering technology developed in-house, iNtRON Bio has secured a new drug candidate payloaded with a substance that effectively eliminates colibactin ,a major causative agent of colorectal cancer and have filed a related US patent application. The phage engineering technology IMPA™ (Intelligent Modular Phage Assembly) was formerly known as the "robot bacteriophage." With the recent US patent application, it was named to clearly reflect the function as a technology for engineering modular phages (mock-up phages) that can carry therapeutic payloads. This achievement is the result of combining transposon mutagenesis, CRISPR/Cas-based forward/reverse genetics, and AI-driven analysis capabilities to explore the possibility of delivering various functional payloads. In particular, it is highly significant that iNtRON Bio successfully loaded a payload targeting colibactin ,deeply involved in colorectal cancer, onto the surface of the phage and, for the first time globally, confirmed its effectiveness. In other words, iNtRON Bio has demonstrated a dual-targeting therapeutic approach that not only eliminates pks+ E. coli, which is a main cause of colorectal cancer, but also neutralizes the toxin secreted by this bacterium. This includes verifying colibactin's role in cancer development, confirming the suppressive effect of modular phage on colorectal cancer, and proving the phage's colibactin-degrading ability—resulting in successful proof-of-concept studies and related patent acquisition. Simply put, the core of this development is that a colibactin-degrading protein was applied as a payload on the phage's protein shell, known as the capsid. Like a precision-guided missile with a warhead, the engineered phage specifically infects pks+ E. coli, kills the bacteria, and at the same time removes the colibactin toxin already secreted by the bacterium using the enzyme carried in the capsid—offering a dual therapeutic effect. Recently, the field of bacteriophage engineering is gaining attention globally. IMPA™ technology is not only a unique platform technology differentiated from other companies, but also serves as strong evidence that it can function as an actual drug delivery platform beyond simple research use. It is encouraging that iNtRON Bio's research has overcome key limitations of conventional phage-based technologies, such as decreased payload activity and phage structural instability when therapeutic substances are loaded. By confirming that the payload retains its original function, iNtRON Bio has demonstrated that it has successfully overcome high technical hurdles. The engineered phages are not merely for research purposes but were selected and validated through multiple tests with real-world and human applications in mind. iNtRON Bio has applied an advanced AI-driven optimization platform technology, refined it with great care, and plan to extend its application to other development fields for ongoing innovation. This achievement is not only a remarkable advancement in phage engineering technology but will also become a driving force for discovering innovative microbiome drug candidates through integration with other phage-based platform technologies of iNtRON Bio. It will proceed smoothly with preclinical studies including proof-of-concept (PoC) testing for combination effects with existing colorectal cancer therapies. In addition, IMPA™ phage engineering technology will be applied more broadly to ADC drug development, anti-cancer agent, and vaccines, as iNtRON Bio continues to strengthen our global technological competitiveness in these fields.
Korea Herald
5 hours ago
- Korea Herald
Precision-Matched Meat Sourcing: The Global Advantage at FHC2025
SHANGHAI, Aug. 5, 2025 /PRNewswire/ -- FHC Shanghai Global Food Trade Show, Asia's flagship international food trade fair, returns to the Shanghai New International Expo Centre (SNIEC) from November 12-14, 2025. China's Visa Policy Opens Doors for Global Meat Commerce Leveraging China's expansive visa-free access for 54 nations, FHC2025 presents an unrivaled opportunity for the international meat industry. Suppliers and buyers gain frictionless entry for pivotal 15-day business engagements. Exhibitors enjoy expedited entry with invitations and 24-hour visa-on-arrival at key ports like Shanghai. Discover the Future of Meat at Asia's Premier Food Epicenter Occupying 200,000 sqm, FHC2025 spotlights the meat sector, building on 2024's resounding success (171,828 trade visitors, 3,000+ global exhibitors). Dedicated showcases from leading meat nations will be unveiled. Expect robust participation from international pavilions representing key players like Brazil, the USA, the EU, and Australia. Witness the convergence of global trends: premium and specialty cuts, sustainable sourcing and traceability solutions, advanced processing technologies, and the booming ready-to-eat/cook segments, all within Shanghai. Precision-Matched Connections with High-Value Meat Buyers The globally acclaimed FHC Hosted Buyer Program offers meat suppliers priority access to high-value procurement channels. Participants gain: Guaranteed High-Impact Meetings: Secure 50+ pre-vetted appointments with premium hotel procurement directors, chain restaurant central kitchen heads, and specialized meat importers. Direct Access to Decision Makers: Engage F&B association leaders and hospitality group executives face-to-face, slashing negotiation cycles by 60%. Actionable Market Intelligence: Gain critical insights into China's $150 billion meat market dynamics and evolving import regulations. VIP Advantage: Enjoy all VIP benefits including access to the VIP Lounge, welcome package and accommodation during the exhibition period (Only for VIP delegations).
